Anavex Life Sciences (Nasdaq: AVXL) recently presented pivotal findings from its Phase IIb/III trial investigating blarcamesine (ANAVEX®2-73), an investigational drug for early Alzheimer’s disease. The once daily oral dementia treatment demonstrated a significant slowing in cognitive decline in patients, reinforcing its potential as a convenient and scalable therapeutic option for Alzheimer’s disease.
At the 2024 Alzheimer’s Association International Conference, data revealed that blarcamesine administered in 50 mg and 30 mg doses significantly reduced clinical progression at 48 weeks by 38.5% and 34.6%, respectively, compared to placebo, based on the primary cognitive endpoint ADAS-Cog13. This outcome is particularly noteworthy, as the ADAS-Cog13 is recommended by the FDA for use as a sole primary endpoint in early Alzheimer’s disease trials.
Key Trial Outcomes
The trial results highlight the efficacy of blarcamesine in both cognition and neurodegeneration markers. Besides the significant cognitive improvements measured by ADAS-Cog13, the secondary endpoint, Clinical Dementia Rating-Sum of Boxes (CDR-SB), also showed marked improvement at both dosage levels. These data suggest that blarcamesine’s ability to target multiple aspects of Alzheimer’s pathology could be central to its effectiveness.
Blarcamesine’s influence extended beyond cognitive measures. MRI scans showed a 37.6% reduction in brain atrophy, with significant preservation of total grey matter (63.5% reduction in atrophy) and lateral ventricles (25.1% reduction). These neuroimaging results are significant in Alzheimer’s research, as brain atrophy is closely associated with cognitive decline.
Notably, the treatment was not associated with neuroimaging adverse events such as Amyloid-related imaging abnormalities (ARIA), a concern with other anti-amyloid therapies. This sets blarcamesine apart as a safer, less invasive option that does not require routine MRI monitoring.
Safety Profile and Mechanism of Action
Blarcamesine’s safety profile is another distinguishing feature of the drug. The most common side effect was dizziness, reported in 35.8% of participants during titration, but these events were generally mild and transient. Importantly, these side effects were manageable by adjusting the titration schedule, offering flexibility in patient management.
The drug’s mechanism targets the SIGMAR1 receptor, which is believed to help regulate cellular processes, including autophagy, a crucial mechanism for clearing protein aggregates in neurodegenerative diseases. This precision medicine approach allows blarcamesine to address Alzheimer’s pathology upstream by enhancing the brain’s natural clearance processes, potentially offering an advantage over existing treatments that focus primarily on amyloid clearance.
Implications for Alzheimer’s Treatment
With a novel mechanism of action and an oral, once daily administration, blarcamesine could address key challenges in Alzheimer’s treatment, particularly access and compliance. Its non-invasive nature, coupled with a good safety profile, positions it as a strong candidate for broader use among patients with early Alzheimer’s disease.
The positive outcomes in the Phase IIb/III trial support Anavex Life Sciences’ plans to submit a regulatory filing to the European Medicines Agency (EMA) in Q4 2024. This filing marks a critical step toward making blarcamesine a widely available treatment option for Alzheimer’s disease.
Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development at Anavex, emphasized that this once daily oral dementia treatment could potentially give patients more time to engage in meaningful activities by slowing disease progression. As the disease continues to affect millions globally, such advancements are vital in addressing the unmet needs in Alzheimer’s treatment.
The results from Anavex Life Sciences’ Phase IIb/III trial underline the potential of blarcamesine as a groundbreaking therapy for Alzheimer’s disease. Its oral administration, ability to target multiple neurodegenerative processes, and manageable safety profile make it a strong contender in the field of dementia treatment. With regulatory submissions planned, Anavex Life Sciences continues to push the boundaries in developing effective treatments for neurodegenerative diseases.
Follow Us